ConductScience.org, home

Paper42444360

Revisiting Insulin Resistance in the Pathophysiology of Type 2 Diabetes Mellitus: A Multi-Organ Perspective.

Lim S and 2 others. Diabetes Metab J, 2026. Cited by 0 papers, by iCite.

Cite this record

ConductScience Library. Revisiting Insulin Resistance in the Pathophysiology of Type 2 Diabetes Mellitus: A Multi-Organ Perspective. Papers, record 42444360. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42444360

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Revisiting Insulin Resistance in the Pathophysiology of Type 2 Diabetes Mellitus: A Multi-Organ Perspective.
PubMed
Journal
Diabetes Metab J
PubMed
Year
2026
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
0
iCite
Revised in PubMed
2026-08-13
PubMed

Authors3

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Lim SSoo
2Lee SHSeung-Hwan
3Eckel RHRobert H

Source PubMed

Download CSV of authors

Topics6

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Insulin ResistanceMajor topic
Diabetes Mellitus, Type 2Major topic
Humans
Metabolic Syndrome
Cardiovascular Diseases
Animals

Grants2

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
Korea Health Industry Development InstitutePubMed
RS-2025-02214302Ministry of Health and WelfarePubMed

Source PubMed

Download CSV of grants

References203

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
125287287Branched-chain amino acids in metabolic signalling and insulin resistance.Nat Rev Endocrinol2014https://conductscience.org/library/papers/25287287PubMed
237840095Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial.Nat Med2023https://conductscience.org/library/papers/37840095PubMed
338152989Metabolic Communication by SGLT2 Inhibition.Circulation2024https://conductscience.org/library/papers/38152989PubMed
427707707Insulin resistance in chronic kidney disease: a systematic review.Am J Physiol Renal Physiol2016https://conductscience.org/library/papers/27707707PubMed
531776781Thiazolidinediones: the Forgotten Diabetes Medications.Curr Diab Rep2019https://conductscience.org/library/papers/31776781PubMed
628045402Inflammatory mechanisms linking obesity and metabolic disease.J Clin Invest2017https://conductscience.org/library/papers/28045402PubMed
740249765Prevalence of Hypercortisolism in Difficult-to-Control Type 2 Diabetes.Diabetes Care2025https://conductscience.org/library/papers/40249765PubMed
840137132The Functions of Major Gut Microbiota in Obesity and Type 2 Diabetes.Metabolites2025https://conductscience.org/library/papers/40137132PubMed
937385275Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial.Lancet2023https://conductscience.org/library/papers/37385275PubMed
1030731283Does nonalcoholic fatty liver disease cause cardiovascular disease? Current knowledge and gaps.Atherosclerosis2019https://conductscience.org/library/papers/30731283PubMed
1140825340Once-weekly semaglutide 2·4 mg in an Asian population with obesity, defined as BMI ≥25 kg/m2, in South Korea and Thailand (STEP 11): a randomised, double-blind, placebo-controlled, phase 3 trial.Lancet Diabetes Endocrinol2025https://conductscience.org/library/papers/40825340PubMed
1231081592A review of the mechanism of action, metabolic profile and haemodynamic effects of sodium-glucose co-transporter-2 inhibitors.Diabetes Obes Metab2019https://conductscience.org/library/papers/31081592PubMed
1330317615Insulin resistance: Review of the underlying molecular mechanisms.J Cell Physiol2019https://conductscience.org/library/papers/30317615PubMed
1429223443Response to Pioglitazone in Patients With Nonalcoholic Steatohepatitis With vs Without Type 2 Diabetes.Clin Gastroenterol Hepatol2018https://conductscience.org/library/papers/29223443PubMed
1538650100Glucagon-Like Peptide-1: New Regulator in Lipid Metabolism.Diabetes Metab J2024https://conductscience.org/library/papers/38650100PubMed
1639231651Physiological and pathophysiological actions of insulin in the liver.Endocr J2025https://conductscience.org/library/papers/39231651PubMed
174135889910. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes-2026.Diabetes Care2026https://conductscience.org/library/papers/41358899PubMed
1835468325
Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial.
Lancet Diabetes Endocrinol2022https://conductscience.org/library/papers/35468325PubMed
1910102702Effects of weight loss on regional fat distribution and insulin sensitivity in obesity.Diabetes1999https://conductscience.org/library/papers/10102702PubMed
2031048405Accumulation of saturated intramyocellular lipid is associated with insulin resistance.J Lipid Res2019https://conductscience.org/library/papers/31048405PubMed

See all 203 referencesDownload CSV of references

Cited by3

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 0 citations.

PMIDTitleJournalYearIn PapersSource
42941840SGLT2 Inhibition Combined with Zn Supplementation Protects the Liver-Pancreas Axis in Experimental Type 2 Diabetes.Int J Mol Sci2026https://conductscience.org/library/papers/42941840PubMed
42926917Comparative effects of aged and newly produced white tea on glucose and lipid metabolism and the gut microbiota in mice with high-fat diet-induced obesity.Curr Res Food Sci2026https://conductscience.org/library/papers/42926917PubMed
42883700Mitochondrial Dynamics in Diabetes Mellitus and Its Complications: Mechanisms, Pathological Roles, and Therapeutic Implications.Int J Mol Sci2026https://conductscience.org/library/papers/42883700PubMed

Download CSV of cited by

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
INS3630PubTator's text mininghttps://conductscience.org/library/genes/3630

Source NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/42444360

GET https://conductscience.org/api/papers/v1/42444360/references?page=2